Overview

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Status:
RECRUITING

Trial end date:
2030-07-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Phase:

PHASE3

Details

Lead Sponsor:

Revolution Medicines, Inc.